Yacktman Asset Management's Q2 2025 13F portfolio value dipped slightly to $7.44B. Click here to read more about the ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

PNC Financial Services Group Inc. trimmed its Johnson & Johnson holdings by 0.5%, now controlling around 6 million shares.

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday.

A phase 3, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for treatment of type 2 diabetes mellitus (T2DM) in children and adolescents.

Johnson & Johnson witnessed a notable increase in interest from Private Advisory Group LLC, which upped its holdings by 61.8% ...

Palantir Technologies Inc. reports stellar Q2 results with soaring US revenue and strong growth across segments. Click for my ...

Johnson & Johnson (NYSE: JNJ) is one of the top cheap pharmaceutical stocks to buy now. On July 29, Johnson & Johnson ...

Johnson & Johnson reported strong second-quarter 2025 earnings results wherein both top and bottom lines beat the Zacks ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.